HPV Treatment Study

Clinical Study Details

Human papillomavirus (HPV) is the most common sexually transmitted infection, and it is estimated that 85% of all women will be infected during their lifetime, often without experiencing symptoms.

Some types of HPV are called high risk HPV as they are associated with an increased risk of cervical cancer which is the fourth most common cancer in women.

Currently, there are no approved therapeutic treatments for high-risk HPV infections.

We are conducting a study looking at a new investigational treatment for HPV that aims to eliminate HPV infection in affected cells.

You may be eligible to take part in this study if you meet the following criteria:

 

To be eligible you must:

  • People with a cervix aged 25 to 55.
  • Must have at least one test showing a positive high-risk HPV result (such as HPV 16+, HPV 18+ or HPV 12 Other +) at least 12 months before screening.
  • Be in generally good health.

Other inclusion and exclusion criteria apply.

Study duration:

The study will have a duration of approximately 30 weeks and there will be 10 in-person clinic visits.

This study is being run at the following clinics and Approved by Central Adelaide Local Health Network Human Research Ethics Committee (CALHN HREC)

Momentum (AusTrials) Wellers Hill – Brisbane, QLD
Momentum (AusTrials) Taringa – Brisbane, QLD

Register your interest in this study here.
If you would like to learn more about participating in the study please enter your details below and we will be in touch shortly.






    Get in touch with Momentum to deliver your next clinical study

    We work with pharmaceutical companies, contract research organisations and academic research institutes to make clinical trials available to patients.

    REGISTER YOUR INTEREST